Eli Lilly and Company
NDC labeler code: 0002
What is a labeler?
The company whose name is on the package and in the FDA’s National Drug Code (NDC) Directory. It may make the medicine itself or sell medicine made by another company. The first part of every NDC code identifies the labeler.
Official FDA data only
Products, approvals and recalls come from the FDA (NDC Directory, Drugs@FDA, enforcement reports). Recalls are linked to this company by the NDC labeler code on the recalled product.
Questions about your medicine: ask your doctor or pharmacist. In an emergency, call 911.
Prescription medicines
- TirzepatideMounjaro, Zepbound, Mounjaro Kwikpen · 48 products
- Insulin lisproHumalog Kwikpen, Admelog, Humalog · 19 products
- AtomoxetineStrattera, Atoncy · 7 products
- SelpercatinibRetevmo · 6 products
- OrforglipronFoundayo · 6 products
- Mirikizumab-mrkzOmvoh · 5 products
- AbemaciclibVerzenio · 4 products
- DulaglutideTrulicity · 4 products
- IxekizumabTaltz · 4 products
- TadalafilCialis, Alyq, Adcirca · 3 products
- BaricitinibOlumiant · 3 products
- Galcanezumab-gnlmEmgality · 3 products
- Lebrikizumab-lbkzEbglyss · 2 products
- Insulin glargineLantus Solostar, Rezvoglar Kwikpen, Lantus · 2 products
- TeriparatideForteo, Bonsity · 2 products
- RamucirumabCyramza · 2 products
- Insulin efsitora alfa-gobeOnswik Kwikpen · 2 products
- LasmiditanReyvow · 2 products
- PirtobrutinibJaypirca · 2 products
- PemetrexedPemrydi Rtu, Alimta, Pemfexy · 2 products
- WaterSterile Water, Bacteriostatic Water, Insulin Diluting Medium for Kirsty · 1 product
- Florbetapir f 18Amyvid · 1 product
- ImlunestrantInluriyo · 1 product
- Raloxifene hydrochlorideEvista · 1 product
- Donanemab-azbtKisunla · 1 product
- Flortaucipir F-18Tauvid · 1 product
- Insulin humanAfrezza, Humulin R U-500 Kwikpen, Myxredlin · 1 product
FDA applications for these products
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- BLA: Biologics License Application: how a biologic medicine (made from living cells) is approved.
| Approved | Application | Medicine | Sponsor |
|---|---|---|---|
| September 23, 2026 | BLA761408 | Insulin efsitora alfa-gobe ONSWIK | Eli Lilly and Co |
| April 1, 2026 | NDA220934 | Orforglipron FOUNDAYO | Eli Lilly and Co |
| September 25, 2025 | NDA218881 | Imlunestrant INLURIYO | Eli Lilly and Co |
| September 13, 2024 | BLA761306 | Lebrikizumab-lbkz EBGLYSS | Eli Lilly and Co |
| July 2, 2024 | BLA761248 | Donanemab-azbt KISUNLA | Eli Lilly Co |
| April 10, 2024 | NDA218160 | Selpercatinib RETEVMO | Eli Lilly and Co |
| November 8, 2023 | NDA217806 | Tirzepatide ZEPBOUND, ZEPBOUND (AUTOINJECTOR), ZEPBOUND KWIKPEN | Eli Lilly and Co |
| October 26, 2023 | BLA761279 | Mirikizumab-mrkz OMVOH | Eli Lilly and Co |
| January 27, 2023 | NDA216059 | Pirtobrutinib JAYPIRCA | Loxo Oncol |
| May 13, 2022 | NDA215866 | Tirzepatide MOUNJARO, MOUNJARO (AUTOINJECTOR), MOUNJARO KWIKPEN | Eli Lilly and Co |
| December 17, 2021 | BLA761215 | Insulin glargine REZVOGLAR | Eli Lilly Co |
| June 15, 2020 | BLA761109 | Insulin lispro LYUMJEV | Eli Lilly and Co |
| May 28, 2020 | NDA212123 | Flortaucipir F-18 TAUVID | Avid Radiopharms Inc |
| May 8, 2020 | NDA213246 | Selpercatinib RETEVMO | Eli Lilly and Co |
| October 11, 2019 | NDA211280 | Lasmiditan REYVOW | Eli Lilly and Co |
| September 27, 2018 | BLA761063 | Galcanezumab-gnlm EMGALITY | Eli Lilly and Co |
| May 31, 2018 | NDA207924 | Baricitinib OLUMIANT | Eli Lilly and Co |
| September 28, 2017 | NDA208716 | Abemaciclib VERZENIO | Eli Lilly and Co |
| March 22, 2016 | BLA125521 | Ixekizumab TALTZ | Eli Lilly and Co |
| December 16, 2015 | BLA205692 | Insulin glargine BASAGLAR | Eli Lilly and Co |
| May 26, 2015 | BLA205747 | Insulin lispro HUMALOG KWIKPEN | Eli Lilly and Co |
| September 18, 2014 | BLA125469 | Dulaglutide TRULICITY | Eli Lilly and Co |
| April 21, 2014 | BLA125477 | Ramucirumab CYRAMZA | Eli Lilly and Co |
| April 6, 2012 | NDA202008 | Florbetapir f 18 AMYVID | Avid Radiopharms Inc |
| February 4, 2004 | NDA021462 | Pemetrexed ALIMTA | Lilly |
Show the other 8 applications
| Approved | Application | Medicine | Sponsor |
|---|---|---|---|
| November 21, 2003 | NDA021368 | Tadalafil CIALIS | Lilly |
| November 26, 2002 | NDA021318 | Teriparatide FORTEO | Lilly |
| November 26, 2002 | NDA021411 | Atomoxetine STRATTERA | Lilly |
| December 22, 1999 | BLA021017 | Insulin lispro HUMALOG MIX 75/25, HUMALOG MIX 75/25 KWIKPEN, HUMALOG MIX 75/25 PEN | Lilly |
| December 22, 1999 | BLA021018 | Insulin lispro HUMALOG MIX 50/50, HUMALOG MIX 50/50 KWIKPEN, HUMALOG MIX 50/50 PEN | Lilly |
| December 9, 1997 | NDA020815 | Raloxifene hydrochloride EVISTA | Lilly |
| June 14, 1996 | BLA020563 | Insulin lispro, Water HUMALOG, HUMALOG KWIKPEN, HUMALOG PEN | Lilly |
| October 28, 1982 | BLA018780 | Insulin human HUMULIN R, HUMULIN R KWIKPEN, HUMULIN R PEN | Lilly |
The sponsor is the company that holds the FDA application; it can differ from the labeler.
Recall timeline
2024
-
March 12, 2024 · Class II · Completed · D-0445-2024 · Insulin lispro, Water
CGMP Deviations
Sterile Diluent, HUMALOG U-100 (insulin lispro injection), HUMULIN R U-100 REGULAR (insulin human injection), Insulin Lispro Injection u-100, 10 mL, Use ONLY with Insulins listed on carton, Marketed by: Lilly USA, LLC, I
2022
-
April 5, 2022 · Class II · Completed · D-0884-2022 · Dulaglutide
TEMPERATURE ABUSE: Products were exposed to temperatures outside of the products labeled storage conditions
Trulicity (dulaglutide) injection, 0.75 mg/0.5mL once weekly, 4 Single-Dose Pens, Rx only, Eli Lilly and Company, Indianapolis, IN 46285, NDC 0002-1433-80
-
April 5, 2022 · Class I · Completed · D-0882-2022 · Insulin lispro, Water
TEMPERATURE ABUSE: Products were exposed to temperatures outside of the products labeled storage conditions due to inclement weather.
Humalog KwikPen, Insulin lispro injection, U-100, 100 units per mL, 5x3 mL Prefilled Pens per box, Marketed by Lilly USA, LLC, Indianapolis, IN 46285, Box NDC 0002-8799-59, Pen NDC 002-7516-59
2021
-
August 19, 2021 · Class II · Terminated · D-0773-2021 · Dulaglutide
Labeling: Label error on declared strength - autoinjector devices labeled as 0.75 mg / 0.5 mL actually contain 1.5 mg / 0.5 mL of product.
Trulicity (dulaglutide), 0.75 mg/0.5 mL, 4 Single-Dose Pens per box, Rx only, Eli Lilly and Company, Indianapolis, IN 46285, NDC 0002-1433-80
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Next steps
- Find a pharmacy near youAsk which company made your medicine and whether it is recalled
- Latest FDA drug recallsAll companies, newest first
- All drug companiesA to Z
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026